论文部分内容阅读
本文回顾分析了接受含顺铂的联合化疗方案治疗的１１２例晚期非小细胞肺癌的近期和远期疗效。结果：部分缓解２９例，有效率２５．９％；中位生存期８个月，１年、２年、３年、５年生存率分别为３４．８％、８．９％、５．４％、１．７９％。大剂量（５０ｍｇ／ｍ２～１００ｍｇ／ｍ２／次×１天）、中剂量（５０ｍｇ／次×３天）及小剂量（２０／ｍｇ～４０ｍｇ／次×３天～５天）剂量组的有效率分别为３５．１％、３１．６％及１７．９％，大、中剂量组的近期疗效明显优于小剂量组；中位生存期：大剂量组１１个月、中剂量组５个月、小剂量组８．５个月，大、中剂量两组比较差异显著（Ｐ＜０．０５）．中、小剂量组比较无明显差异；本文还提示；ⅢＢ期和Ⅳ期、鳞癌和腺癌的近期、远期疗效相同，部分缓解和稳定者的中位生存期较进展者明显延长（Ｐ＜０．０５）。
This article reviews the short-term and long-term outcomes of 112 patients with advanced non-small cell lung cancer treated with cisplatin-based combination chemotherapy. Results: The partial remission in 29 cases, the effective rate of 25.9%; median survival of 8 months, 1 year, 2 years, 3 years, 5-year survival rates were 34.8%, 8.9%, 5.4 %, 1.79%. The effective rate of high dose (50mg / m2 ~ 100mg / m2 / time × 1 day), medium dose (50mg / time × 3 days) and low dose (20 / mg ~ 40mg / time × 3 days ~ 5 days) Respectively, 35.1%, 31.6% and 17.9% respectively. The short-term curative effect of the large and medium dose groups was significantly better than that of the low dose group. The median survival time was 11 months for the high dose group and 5 months for the medium dose group , Low-dose group 8.5 months, large and medium dose two groups difference was significant (P <0.05). Medium and small dose group no significant difference; this article also prompts; Ⅲ B and Ⅳ, squamous cell carcinoma and adenocarcinoma of the short-term, long-term efficacy of the same, partial response and stability of the median survival was significantly longer than those who progress <0.05).